News Lilly chases Amgen with migraine drug filing Eli Lilly has filed its galcanezumab migraine drug with the FDA, as it looks to claim second place among a group of companies attempting to market a new class of therapies.
News New Teva CEO axes R&D chief Hayden in boardroom shakeup R&D chief Michael Hayden to leave at year end.
News Judge throws out Allergan patents, criticises Native America... Federal court throws out patents on Restasis
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
